Laura Ciaffi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9493245/publications.pdf

Version: 2024-02-01

1683354 1372195 11 211 5 10 citations h-index g-index papers 11 11 11 428 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	APOL1 Renal Risk Variants and Kidney Function in HIV-1–Infected People From Sub-Saharan Africa. Kidney International Reports, 2022, 7, 483-493.	0.4	5
2	Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial). Journal of Antimicrobial Chemotherapy, 2021, 76, 1286-1293.	1.3	4
3	SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. Nature Communications, 2021, 12, 5851.	5.8	38
4	The Follow-Up and Well-Being of Geriatric Outpatients During COVID-19 Pandemic in Cameroon: Insights From the Yaounde Central Hospital. Gerontology and Geriatric Medicine, 2020, 6, 233372142095924.	0.8	5
5	Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting. BMC Nephrology, 2019, 20, 155.	0.8	22
6	Implementation and evaluation of a therapeutic patient education programme during a clinical trial in Yaoundé, Cameroon – Trial ANRS-12286/MOBIDIP. Patient Education and Counseling, 2018, 101, 1262-1269.	.1.0	0
7	Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir. AIDS Research and Human Retroviruses, 2018, 34, 477-480.	0.5	4
8	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq(e384-e392.	0.0 0 rgBT 2.1	Qverlock]
9	Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for	1.0	3
10	Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. AIDS Research and Human Retroviruses, 2016, 32, 1159-1162.	0.5	28
11	Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. Aids, 2015, 29, 1473-1481.	1.0	39